Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cis023DOI Listing

Publication Analysis

Top Keywords

era defining
4
defining optimal
4
optimal treatment
4
treatment invasive
4
invasive candidiasis
4
era
1
optimal
1
treatment
1
invasive
1
candidiasis
1

Similar Publications

Rationale & Objective: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH). We evaluated the incidence of CKD among PLWH compared with HIV-uninfected controls in Tanzania.

Study Design: Prospective cohort study.

View Article and Find Full Text PDF

Aim: To characterize the differences of dynamic changes for absolute lymphocyte count (ALC) among esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (nCRT) with or without pembrolizumab, as well as to investigate the clinical and lymphocyte-related organs dosimetric parameters that would impact ALC nadir during nCRT.

Materials And Methods: A total of 216 ESCC patients who received nCRT (with pembrolizumab 144; without pembrolizumab: 72) were identified from a prospective cohort. Weekly and 1-month post-nCRT ALC were identified.

View Article and Find Full Text PDF

A family with gallstone disease: defining inherited risk in the era of clinical genetic testing.

Intern Emerg Med

January 2025

Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Germany.

Gallstones are among the most frequent hepatobiliary conditions. Although in most cases, they remain asymptomatic, they can cause complications and, in such cases, invasive treatments like endoscopic retrograde cholangiography (ERC) or cholecystectomy are required. Here, we present the results of genetic testing of a single family with a high incidence of symptomatic gallstones and cholestatic liver phenotypes.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Cognivue, Inc., Victor, NY, USA.

Background: An easy and reliable method for detection of Alzheimer's Disease (AD) and mild cognitive impairment (MCI) is critical for clinical trial enrollment. In the era of amyloid-lowering therapies, there is a need to identify individuals likely to have amyloid to enrich recruitment and lower costs related to amyloid PET. In addition, a subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but to date there is no cognitive assessment or screening method that can detect these individuals in the absence of expensive biomarkers.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Background: In the era of disease-modifying treatments for Alzheimer's disease (AD), accurate detection of underlying AD pathology is critical. Blood-based biomarkers for AD are increasingly available, but their diagnostic performance is not well-understood across the spectrum of neurodegenerative disease, especially when AD presents as co-pathology in non-AD syndromes. We investigated the diagnostic performance of three plasma biomarkers (phosphorylated tau 217 [p-tau217], neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) to detect AD, confirmed by autopsy, across 12 clinical neurodegenerative syndromes with various underlying etiologies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!